Transactions
17
Insider / Immunovant, Inc.
Gloria Melanie
Chief Operating Officer at Immunovant, Inc.
- Company
- Immunovant, Inc.
- Ticker
- IMVT
- First filing on record
- November 21, 2025
- Latest trade on record
- October 7, 2026
- SEC filings
- EDGAR ↗
Gloria Melanie, Chief Operating Officer at Immunovant, Inc., has disclosed 17 transactions in IMVT since November 21, 2025: 0 purchases (0 open-market buys) and 15 sales, worth about $1.7M at the reported prices. The latest was filed October 9, 2026, 2 days after the trade.
Open-market buys
0
Sales
15
Avg. disclosure lag
1.6d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Gloria Melanie made no purchases and 15 sales worth $1.7M, plus 2 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Gloria Melanie has traded 1 stock on record; the largest by dollars is IMVT.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 9 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 15 | 52,748 | $1.7M |
| A | Grant or award | 2 | 204,734 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 15 | 0 | 13 · $1.4M |
| 2025 | 2 | 0 | 2 · $298K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| IMVT | Sell S | October 7, 2026 | October 9, 2026 | 2d | 2,241 | $32 | $72K | Form 4 ↗ | ||
| IMVT | Sell S | August 20, 2026 | August 21, 2026 | 1d | 3,056 | $44 | $135K | Form 4 ↗ | ||
| IMVT | Sell S | July 8, 2026 | July 10, 2026 | 2d | 106 | $40 | $4,239 | Form 4 ↗ | ||
| IMVT | Sell S | July 8, 2026 | July 10, 2026 | 2d | 1,930 | $40 | $76K | Form 4 ↗ | ||
| IMVT | Sell S | June 26, 2026 | June 26, 2026 | 0d | 2,966 | $39 | $116K | Form 4 ↗ | ||
| IMVT | Sell S | June 26, 2026 | June 26, 2026 | 0d | 14,748 | $38 | $563K | Form 4 ↗ | ||
| IMVT | Sell S | May 20, 2026 | May 22, 2026 | 2d | 1,698 | $33 | $56K | Form 4 ↗ | ||
| IMVT | Sell S | May 20, 2026 | May 22, 2026 | 2d | 1,168 | $32 | $38K | Form 4 ↗ | ||
| IMVT | Sell S | May 20, 2026 | May 22, 2026 | 2d | 249 | $30 | $7,572 | Form 4 ↗ | ||
| IMVT | Sell S | April 8, 2026 | April 10, 2026 | 2d | 8,722 | $25 | $217K | Form 4 ↗ | ||
| IMVT | Other A | April 7, 2026 | April 9, 2026 | 2d | 121,063 | — | — | derivative | Form 4 ↗ | |
| IMVT | Other A | April 7, 2026 | April 9, 2026 | 2d | 83,671 | — | — | Form 4 ↗ | ||
| IMVT | Sell S | February 25, 2026 | February 27, 2026 | 2d | 942 | $29 | $27K | Form 4 ↗ | ||
| IMVT | Sell S | February 25, 2026 | February 27, 2026 | 2d | 859 | $28 | $24K | Form 4 ↗ | ||
| IMVT | Sell S | February 25, 2026 | February 27, 2026 | 2d | 1,437 | $27 | $39K | Form 4 ↗ | ||
| IMVT | Sell S | November 20, 2025 | November 21, 2025 | 1d | 2,375 | $24 | $57K | Form 4 ↗ | ||
| IMVT | Sell S | November 20, 2025 | November 21, 2025 | 1d | 10,251 | $24 | $241K | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| October 9, 2026 | Form 4 | 0001764013-26-000112 | 1 | published | EDGAR ↗ |
| August 21, 2026 | Form 4 | 0001973838-26-000007 | 1 | published | EDGAR ↗ |
| July 10, 2026 | Form 4 | 0001764013-26-000083 | 2 | published | EDGAR ↗ |
| June 26, 2026 | Form 4 | 0001764013-26-000075 | 2 | published | EDGAR ↗ |
| May 22, 2026 | Form 4 | 0001764013-26-000067 | 3 | published | EDGAR ↗ |
| April 10, 2026 | Form 4 | 0001973838-26-000004 | 1 | published | EDGAR ↗ |
| April 9, 2026 | Form 4 | 0001764013-26-000040 | 2 | published | EDGAR ↗ |
| February 27, 2026 | Form 4 | 0001764013-26-000013 | 3 | published | EDGAR ↗ |
| November 21, 2025 | Form 4 | 0001764013-25-000156 | 2 | published | EDGAR ↗ |
Other insiders at Immunovant, Inc.
- Venker Eric President & Immunovant CEO 94 rows
- Stout Jay S Chief Technology Officer 19 rows
- Pande Atul Director 17 rows
- Torti Frank President and Vant Chair 17 rows
- Van Tuyl Christopher Chief Legal Officer 15 rows
- Fromkin Andrew J. Director 14 rows
- Girao Tiago Chief Financial Officer 7 rows
- Hughes Douglas J. Director 4 rows
- Bauer Jake Director 3 rows
- Susman Robert Graham Director 3 rows
Everyone on file, with contracts and lobbying under the company's name: Immunovant, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 9 | 17 | November 21, 2025 | October 9, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.